Swiss biotech company Noema Pharma secures CHF130m to advance CNS therapies
Basel, Switzerland-based Noema Pharma, a clinical-stage biotech company, has announced the successful close of its Series B financing round extension, securing CHF 130 million (approximately ... Read More
Merck’s WELIREG receives positive CHMP opinion for VHL tumours and advanced RCC
Merck, known as MSD outside the U.S. and Canada, has moved a step closer to offering innovative treatment options in Europe. The European Medicines Agency’s ... Read More
Actinogen Medical progresses in XanaMIA Phase 2b/3 trial for Alzheimer’s disease
Actinogen Medical Limited (ASX: ACW) has announced a major milestone in its ongoing XanaMIA Phase 2b/3 clinical trial, aimed at treating biomarker-positive mild to moderate ... Read More
BeiGene stock surges on EU approval for TEVIMBRA in advanced cancer treatment
BeiGene, a global oncology company, announced that the European Commission has granted regulatory approval for TEVIMBRA (tislelizumab), its PD-1 monoclonal antibody, for the first-line treatment ... Read More
Rallybio Phase 2 trial of RLYB212 begins to tackle FNAIT in high-risk pregnancies
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company known for advancing innovative therapies for rare diseases, has commenced its Phase 2 clinical trial for RLYB212. ... Read More
OncoVerity accelerates AML treatment with Series A extension
OncoVerity, a leader in integrating bioinformatics with oncology drug development, has closed a Series A extension financing round, bolstered by its key investors, argenx and ... Read More
Pharma breakthrough! BioIntelect to revolutionise trials using Opyl’s cutting-edge tech
In a landmark collaboration, Opyl Limited announced a new six-month agreement with BioIntelect, a renowned Clinical Research Organisation (CRO) and strategic consulting firm in the ... Read More
Amplia Therapeutics secures FDA fast track status for narmafotinib in pancreatic cancer, stock surges
Amplia Therapeutics Limited (ASX: ATX) has announced that its Focal Adhesion Kinase (FAK) inhibitor, narmafotinib, has been granted Fast Track Designation by the United States ... Read More
Longboard Pharmaceuticals shares see spike as FDA recognizes potential of bexicaserin in Dravet syndrome
Shares of Longboard Pharmaceuticals, Inc. surged on Thursday after the United States Food and Drug Administration (FDA) granted both Rare Pediatric Disease designation and Orphan ... Read More
Actinogen Medical makes bold A$11.1m move to boost Alzheimer’s drug trial
Actinogen Medical has raised 11.1 million AUD in a significant capital raise led by its CEO, Dr. Steven Gourlay, who personally invested 1 million AUD. ... Read More